1naresh
Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1nareshArray ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) )Table 5:Base case and scenario analyses
Strategy Cost Incremental Cost ($) Effectiveness (QALYs) Incremental Effectiveness Incremental Cost-Effectiveness ICER Base case CEA $24,624 6.83 3605 CAS $30,731 $6107.00 6.71 −0.12 4580 Dominateda SAPPHIRE CEA $77,377 $14,801.48 5.14 −1.96 15049 Dominateda CAS $62,576 7.1 8814 EVA-3S CEA $22585 6.82 $3312 CAS $30,832 $8246.38 6.67 −0.15 $4695 Dominateda CREST CEA $22,259 6.89 $3227 CAS $25,846 $3587.00 6.63 −0.27 $3900 Dominateda
Note:—ICER indicates incremental cost-effectiveness ratio.
↵a “Dominated” means that the treatment modality was associated with more cost and less effectiveness.